HDAC9 and melanoma: In these studies, HDAC inhibitor treatment enhanced the expression of MHC class II, CD40 and B7-1/2 on B16 cells and vaccination with HDAC inhibitor-treated melanoma cells elicited tumor specific immunity in both prevention and treatment models.